Monopar Therapeutics Inc. Common Stock (MNPR)

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasmin…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

22

Website

www.monopartx.com/

Fundamentals

1-day range

$109.28$113.99

Market cap

$747.88M

P/E (trailing)

—

P/E (forward)

-56.51

EPS (trailing)

$-1.90

Dividend yield

—

Beta

1.42

Avg. volume

218.6K

Forecasts

13 analyst ratings

Monopar Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.77$124.82
• PHAR

  Pharming Group N.V. ADS each representing 10 ordinary shares

  $11.7

  ▼ 0.68%
  Market cap $766.28MP/E 88.15
  $0.8338$1.82
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $772.34MP/E —
  $1.74$6.6
• DSGN

  Design Therapeutics Inc. Common Stock

  $15.12

  ▼ 0.85%
  Market cap $796.95MP/E —
  $5.04$17.25
• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
  Yahoo · 8/19/2026
• Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
  SeekingAlpha · 8/18/2026
• Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
  benzinga · 8/13/2026
• This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
  Benzinga · 8/13/2026
• Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
  Benzinga · 8/13/2026
• Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
  Benzinga · 8/13/2026
• BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
  Benzinga · 8/12/2026
• Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
  Yahoo · 8/12/2026
• Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
  Benzinga · 8/12/2026

• Kim R. Tsuchimoto · August 26, 2026 · Option Exercise

  2.0K @ $14
• Kim R. Tsuchimoto · August 26, 2026 · Option Exercise

  2.1K @ $30
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  590 @ $113.84
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  602 @ $112.93
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  1.1K @ $111.84
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  700 @ $110.65
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  615 @ $109.56
• Kim R. Tsuchimoto · August 26, 2026 · Sale

  485 @ $108.83
• RIOUX PATRICE · August 26, 2026 · Option Exercise

  1.4K @ $0.005
• RIOUX PATRICE · August 26, 2026 · Sale

  1 @ $111.26
• Anderson Raymond · August 25, 2026 · Option Exercise

  1.7K @ $30
• Anderson Raymond · August 25, 2026 · Option Exercise

  1.4K @ $30
• Anderson Raymond · August 25, 2026 · Sale

  1.8K @ $113.05
• Anderson Raymond · August 25, 2026 · Sale

  646 @ $110.07
• Anderson Raymond · August 25, 2026 · Sale

  694 @ $110.04

Institutional Ownership

March 31, 2026

Total shares held

6.16M

Total value held

$334.61M

Institutional holders

77